Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
**Background/Objectives:** Until now, no meta-analysis has been published to evaluate the diagnostic performance of next-generation sequencing (NGS) panel using circulating tumor (ctDNA) in patients with advanced non-small cell lung cancer (aNSCLC). The aim of the study was to carry out a systematic...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2020-09-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/jheor.2020.17088 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860352659488768 |
|---|---|
| author | Mariana M. Sebastião Rodrigo S. Ho João Paulo V. de Carvalho Micha Nussbaum |
| author_facet | Mariana M. Sebastião Rodrigo S. Ho João Paulo V. de Carvalho Micha Nussbaum |
| author_sort | Mariana M. Sebastião |
| collection | DOAJ |
| description | **Background/Objectives:** Until now, no meta-analysis has been published to evaluate the diagnostic performance of next-generation sequencing (NGS) panel using circulating tumor (ctDNA) in patients with advanced non-small cell lung cancer (aNSCLC). The aim of the study was to carry out a systematic review and a meta-analysis in order to determine the accuracy of NGS of ctDNA to detect six oncogenic driver alterations: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-RAF (BRAF); RET proto-oncogene (RET); and MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 in patients with aNSCLC.
**Methods:** MEDLINE/PubMed, Cochrane Library, Latin American and Caribbean Health Sciences Literature (LILACS), and Centre for Reviews and Dissemination databases and articles obtained from other sources were searched for relevant studies that evaluate the accuracy (sensitivity and specificity) of NGS using ctDNA in patients with aNSCLC. The studies were eligible when NGS of ctDNA was compared with tissue tests to detect at least one of the six oncogenic driver alterations. Diagnostic measures (sensitivity and specificity) were pooled with a bivariate diagnostic random effect. All statistical analyses were performed with software R, v.4.0.0.
**Results:** Ten studies were eligible for data extraction. The overall pooled estimates of sensitivity and specificity were 0.766 (95% CI: 0.678-0.835); 0.999 (95% CI: 0.990-1.000), respectively.
**Conclusions:** The analysis has demonstrated that the NGS panel using ctDNA has a high accuracy to identify the six actionable oncogenic driver alterations in patients with aNSCLC. Therefore, it can be considered a reliable alternative to guide the patients with aNSCLC to the right treatment who cannot undergo an invasive procedure or have insufficient tissue material for molecular tests. |
| format | Article |
| id | doaj-art-812fcaaef22c491486bb6a58fa7cc276 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-812fcaaef22c491486bb6a58fa7cc2762025-02-10T16:13:03ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362020-09-0172Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisMariana M. SebastiãoRodrigo S. HoJoão Paulo V. de CarvalhoMicha Nussbaum**Background/Objectives:** Until now, no meta-analysis has been published to evaluate the diagnostic performance of next-generation sequencing (NGS) panel using circulating tumor (ctDNA) in patients with advanced non-small cell lung cancer (aNSCLC). The aim of the study was to carry out a systematic review and a meta-analysis in order to determine the accuracy of NGS of ctDNA to detect six oncogenic driver alterations: epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); ROS proto-oncogene 1, receptor tyrosine kinase (ROS-1); serine/threonine-protein kinase B-RAF (BRAF); RET proto-oncogene (RET); and MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 in patients with aNSCLC. **Methods:** MEDLINE/PubMed, Cochrane Library, Latin American and Caribbean Health Sciences Literature (LILACS), and Centre for Reviews and Dissemination databases and articles obtained from other sources were searched for relevant studies that evaluate the accuracy (sensitivity and specificity) of NGS using ctDNA in patients with aNSCLC. The studies were eligible when NGS of ctDNA was compared with tissue tests to detect at least one of the six oncogenic driver alterations. Diagnostic measures (sensitivity and specificity) were pooled with a bivariate diagnostic random effect. All statistical analyses were performed with software R, v.4.0.0. **Results:** Ten studies were eligible for data extraction. The overall pooled estimates of sensitivity and specificity were 0.766 (95% CI: 0.678-0.835); 0.999 (95% CI: 0.990-1.000), respectively. **Conclusions:** The analysis has demonstrated that the NGS panel using ctDNA has a high accuracy to identify the six actionable oncogenic driver alterations in patients with aNSCLC. Therefore, it can be considered a reliable alternative to guide the patients with aNSCLC to the right treatment who cannot undergo an invasive procedure or have insufficient tissue material for molecular tests.https://doi.org/10.36469/jheor.2020.17088 |
| spellingShingle | Mariana M. Sebastião Rodrigo S. Ho João Paulo V. de Carvalho Micha Nussbaum Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Journal of Health Economics and Outcomes Research |
| title | Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_full | Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_fullStr | Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_short | Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
| title_sort | diagnostic accuracy of next generation sequencing panel using circulating tumor dna in patients with advanced non small cell lung cancer a systematic review and meta analysis |
| url | https://doi.org/10.36469/jheor.2020.17088 |
| work_keys_str_mv | AT marianamsebastiao diagnosticaccuracyofnextgenerationsequencingpanelusingcirculatingtumordnainpatientswithadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT rodrigosho diagnosticaccuracyofnextgenerationsequencingpanelusingcirculatingtumordnainpatientswithadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT joaopaulovdecarvalho diagnosticaccuracyofnextgenerationsequencingpanelusingcirculatingtumordnainpatientswithadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis AT michanussbaum diagnosticaccuracyofnextgenerationsequencingpanelusingcirculatingtumordnainpatientswithadvancednonsmallcelllungcancerasystematicreviewandmetaanalysis |